Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-ammonium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes

A technology for dimethylpropane and diabetes, applied to the use of 3-carboxy-N-ethyl-N,N-dimethylpropane-1-ammonium or its pharmaceutically acceptable salt in the prevention and treatment of diabetes areas that can address issues such as inadequate insulin control

Active Publication Date: 2018-03-02
GRINDEKS
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also due to inadequate insulin control, achieving and maintaining long-term glycemic control with existing medications is often challenging in T2DM patients (MANNINO G.C., SESTIG. Individualized Therapy for Type 2 Diabetes: Clinical Implications of Pharmacogenetic Data. Mol Diagn Ther. 2012, vol.16, p.285-302; SAFAVI M., et al.The importance of synthetic drugs for type 2diabetes drug discovery.Expert OpinDrug Discov.Ahead of Print(doi:10.1517 / 17460441.2013.837883).19.09.2013, p.1-25)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-ammonium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
  • Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-ammonium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0012] Female ApoE weighing 18-20g - / - Mice were kept in an air-conditioned room (22.5±0.5°C, 50±5% humidity) with a light-dark cycle of 12h dark / 12h light, with unrestricted access to food and water.

[0013] Mice were acclimated to the area environment for 1 week before starting the study. At 8 weeks of age, mice were randomly assigned to 5 equally sized groups (n=10). Experimental animals in all groups were fed WESTERN RD(P) diet (Cat 82316) from Special Diets Services (UK) for 4 months. During this 4-month period, mice in different experimental groups received the following treatments:

[0014] Control group – drinking water;

[0015] GBB group – GBB 10mg / kg;

[0016] 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium hydrogen fumarate group – 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium rich Hydrogen maleate 17.5mg / kg;

[0017] 3-Carboxy-N-ethyl-N,N-dimethylpropane-1-ammonium dihydrogen phosphate group – 3-Carboxyl-N-ethyl-N,N-dimethylpropane-1-ammonium phosphate di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium and pharmaceutically acceptable salts thereof for reducing plasma insulin and glucose levels.

Description

technical field [0001] The present invention relates to 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium or a pharmaceutically acceptable salt thereof for preventing and treating diabetes. Examples of pharmaceutically acceptable salts of 3-carboxy-N-ethyl-N,N-dimethylprop-1-ammonium are: 3-carboxy-N-ethyl-N,N-dimethylpropane- 1-Ammonium hydrogen fumarate and 3-carboxy-N-ethyl-N,N-dimethylprop-1-ammonium dihydrogen phosphate. Background technique [0002] It is known that 3-carboxy-N,N,N-trimethylpropan-1-ammonium (GBB) is mainly a biological precursor of carnitine, a key molecule regulating myocardial energy metabolism. It was initially characterized as a toxic substance that accelerates respiration, causes salivation and lacrimation, mydriasis, vasoconstriction and diastolic cardiac arrest (LINNEWEH W. Gamma-Butyrobetain, Crotonbetain und Carnitin im tierischen Stoffwechsel. Hoppe-Seylers Zeitschrift fur physiologische Chemie. 1929, vol. 181, p. 42-53). In subsequent publ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/205C07C227/08C07C229/12
CPCA61K31/205
Inventor 马尧伊·达姆布罗瓦海伦娜·奇鲁尔伊瓦尔斯·卡尔温斯埃德加斯·利平斯叶琳娜·马卡罗娃伊尔马斯·斯托南斯伊尔加·米萨内
Owner GRINDEKS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap